Loading...
XCSEORPHA
Market cap5mUSD
Nov 19, Last price  
939.00DKK
Name

Orphazyme A/S

Chart & Performance

D1W1MN
XCSE:ORPHA chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-68.86%
Rev. gr., 5y
51.66%
Revenues
0k
Net income
-633m
L+87.63%
-47,714,000-57,935,000-126,204,000-229,600,000-337,497,000-633,246,000
CFO
-539m
L+64.95%
-46,414,000-54,727,000-95,426,000-234,764,000-326,818,000-539,076,000

Profile

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
IPO date
Nov 17, 2017
Employees
1
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFY
2020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT